TransMedics (TMDX) Short term Debt (2025 - 2026)

TransMedics (TMDX) posted quarterly Short term Debt of $15.0 million for Q1 2026, up 50.0% quarter-over-quarter from $10.0 million in Q4 2025.

TransMedics (TMDX) Short term Debt (2025 - 2026) Analysis & Trends

TransMedics' Short term Debt history runs 2 years deep, the most recent figure standing at $15.0 million for Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (changed N/A YoY), while the FY2025 annual figure was $10.0 million, changed N/A from the prior year.
Short term Debt for Q1 2026 stood at $15.0 million, up from $10.0 million in the prior quarter.
The five-year high for Short term Debt was $15.0 million in Q1 2026, with the low at $5.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	TransMedics	3.15 Bn	2.67 Bn	113.20 Mn

Download Data